HealthTech Innovation Days

Pepkon

Description

PepKon is a French biotech start-up developing first-in-class therapeutic peptides for refractory or relapsed cancers. Leveraging ten years of academic research, its lead candidate is a CD47 agonist derived from thrombospondin-1. It acts through a novel, calcium-dependent and selective mechanism of action that kills cancer cells while sparing healthy ones. It has shown remarkable efficacy across various cancer types, including orphan and incurable leukemias regardless of prognosis or resistance markers. Backed by a vetted team of 13 persons and €5M in funding, PepKon plans to complete preclinical studies and begin clinical trials by 2026, with a Series A funding round in 2025.

Our Sessions